Anteris Technologies Global Corp. Common Stock (AVR) is a publicly traded Healthcare sector company. As of May 21, 2026, AVR trades at $8.65 with a market cap of $736.88M and a P/E ratio of -3.72. AVR moved +12.08% today. Year to date, AVR is +80.33%; over the trailing twelve months it is +125.65%. Its 52-week range spans $2.34 to $8.79. Analyst consensus is strong buy with an average price target of $16.00. Rallies surfaces AVR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Anteris Price Target Raised to $18, Highlighting 148% Upside on Trial Progress: Barclays boosted its price target for Anteris Technologies to $18.00, implying 148.3% upside from the $7.25 stock price. The company is enrolling patients in its global PARADIGM pivotal trial across the US and Europe, backed by a $320 million capital raise and new board appointees.
| Metric | Value |
|---|---|
| Price | $8.65 |
| Market Cap | $736.88M |
| P/E Ratio | -3.72 |
| EPS | $-2.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.79 |
| 52-Week Low | $2.34 |
| Volume | 2.06K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.85M |
| Net Income | $-95.19M |
| Gross Margin | 74.28% |
4 analysts cover AVR: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $16.00.